drugset / Trial / NCT03367871
Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer
NaSingle-groupOpen-labelTreatment
Summary
The investigators propose to evaluate the efficacy of the combination of standard chemotherapy with bevacizumab with Pembrolizumab in women with recurrent, persistent, or metastatic cervical cancer.
Timeline
- Start
- 2018-09-06
- Primary completion
- 2023-01-30
- Completion
- 2023-01-30
Outcome
Outcome not reported
Stopped: “Investigator left institution”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Subject | Carboplatin | Small molecule | 5 unknown | Intravenous |
| Subject | Cisplatin | Other / unclassified | 50 mg/m2 | Intravenous |
| Subject | Paclitaxel | Small molecule | 135 mg/m2 | Intravenous |
| Subject | Paclitaxel | Small molecule | 175 mg/m2 | Intravenous |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | — |